Phase I study of H5.020CMV.PDGF-β to treat venous leg ulcer disease

David J. Margolis, Lee M. Morris, Maryte Papadopoulos, Linda Weinberg, Jennifer C. Filip, Stephanie A. Lang, Sachin S. Vaikunth, Timothy M. Crombleholme

Research output: Contribution to journalArticlepeer-review

38 Scopus citations


Venous leg ulcers are a prevalent nonhealing wound of the lower extremity. Although topically applied growth factors successfully improve wound repair in animal studies, similar studies on humans with venous leg ulcers have not been successful. This study was designed to evaluate the acute safety and biologic feasibility of peri-ulcer injection of a replication-incompetent adenoviral construct expressing platelet-derived growth factor-β (PDGF-β). In this phase I study, we demonstrate the initial safety, feasibility, and biologic plausibility of using H5.020CMV.PDGF-β to treat venous leg ulcer disease.

Original languageEnglish (US)
Pages (from-to)1822-1829
Number of pages8
JournalMolecular Therapy
Issue number10
StatePublished - 2009

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Genetics
  • Pharmacology
  • Drug Discovery


Dive into the research topics of 'Phase I study of H5.020CMV.PDGF-β to treat venous leg ulcer disease'. Together they form a unique fingerprint.

Cite this